Live Breaking News & Updates on Y Alan Wang

Stay updated with breaking news from Y alan wang. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Proactive Investors China - The web's leading portal for China stocks - Charlie Teo Foundation grant to fund key research of new Pharmaxis drug to tackle brain cancer


2021-05-03
by Proactive Australia
Pharmaxis Ltd (ASX:PXS)(FRA:UUD) drug discovery PXS-5505 will be the focus of a new study funded by a grant from the Charlie Teo Foundation, an Australian charity, for key research into a drug discovery tackling an aggressive and deadly form of brain cancer.
The drug, PXS-5505, which has commenced a phase 1/2a clinical trial for the rare bone marrow cancer myelofibrosis, will now enter pre-clinical efficacy testing for glioblastoma (GBM), the most common form of brain cancer with an average survival of only 15 months from diagnosis.
A$186,837 research grant
Charlie Teo Foundation has awarded a A$186,837 research grant to Y Alan Wang, PhD, associate professor of Cancer Biology at The University of Texas MD Anderson Cancer Center to enable the study of PXS-5505. ....

United States , Gary Phillips , Y Alan Wang , University Of Texas Md Anderson Cancer Center , Pharmaxis Ltd , Charlie Teo Foundation , Teo Foundation , Cancer Biology , Cancer Center , China Small Caps , Small Caps , China Small Capos Fund , Hong Kong , Invest Info , Penny Shares , Stock Markets , Stock Exchanges , Small Cap Stocks , Inancial News , Mining News , Il And Gas News , ஒன்றுபட்டது மாநிலங்களில் , கேரி பிலிப்ஸ் , பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் ம்ட் ஆண்டர்சன் புற்றுநோய் மையம் , சார்லி டேயொ அடித்தளம் , புற்றுநோய் உயிரியல் ,

Charlie Teo Foundation grant to fund key research of new Pharmaxis Ltd drug to tackle brain cancer


Charlie Teo Foundation grant to fund key research of new Pharmaxis drug to tackle brain cancer
PXS-5505 will enter pre-clinical efficacy testing for glioblastoma, the most common form of brain cancer with an average survival of only 15 months from diagnosis.
Charlie Teo Foundation founder and director Professor Charlie Teo and Pharmaxis CEO Gary Phillips during a TV interview.
Pharmaxis Ltd (ASX:PXS) (FRA:UUD) drug discovery PXS-5505 will be the focus of a new study funded by a grant from the Charlie Teo Foundation, an Australian charity, for key research into a drug discovery tackling an aggressive and deadly form of brain cancer. ....

United States , Gary Phillips , Y Alan Wang , Charlie Teo , University Of Texas Md Anderson Cancer Center , Charlie Teo Foundation , Teo Foundation , Cancer Biology , Cancer Center , Lancet Neurol , Professor Charlie Teo , Small Caps , Harma Biotech , Pharmaxis Ltd , Asx Pxs , ஒன்றுபட்டது மாநிலங்களில் , கேரி பிலிப்ஸ் , சார்லி டேயொ , பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் ம்ட் ஆண்டர்சன் புற்றுநோய் மையம் , சார்லி டேயொ அடித்தளம் , புற்றுநோய் உயிரியல் , புற்றுநோய் மையம் , ப்ரொஃபெஸர் சார்லி டேயொ , சிறிய தொப்பிகள் ,